Compare Cloudflare Inc (NET) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cloudflare Inc vs BIO-TECHNE Corp — how do they compare? Cloudflare Inc trades at $270.81 (market cap $96.69B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Cloudflare Inc is far larger — about 8.7× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Cloudflare Inc pays none. Which is the better fit depends on your goals.
| NET | TECH | |
|---|---|---|
Market Cap | $96.69B | $11.16B |
Sector | Technology | Health |
52-Week High | $281.69 | $72.12 |
52-Week Low | $160.16 | $43.31 |
Enterprise Value | $96.05B | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cloudflare (NET) trades at $272.20, down 1.95% over 24 hours, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats but remains unprofitable, with a negative net income margin of -3.72% despite robust revenue growth to $2.17 billion in 2025. Operating cash flow improved to $603 million, though high valuation multiples like P/S of 40.96 and EV/EBITDA of 696.61 reflect premium pricing. Recent news highlights institutional interest and cybersecurity sector tailwinds.
Outlook is cautiously optimistic given analyst consensus of 72.5% buy ratings and a $271 price target near current levels. Key opportunities include AI-driven cybersecurity demand and revenue momentum, but risks encompass persistent losses, elevated debt, and competitive pressures. Investors should weigh growth potential against profitability challenges and market volatility.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
